Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

作者：Raphael J. Landovitz, Sue Li, Joseph J. Eron, Beatriz Grinsztejn, Halima Dawood, Albert Liu, Manya Magnus, Mina C. Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A. Marzinke, Susan H. Eshleman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R. Rinehart, David M. Margolis, Myron S. Cohen, Marybeth McCauley, Craig W. Hendrix · 发表于：The Lancet HIV · 年份：2020 · DOI：10.1016/s2352-3018(20)30106-5 · 被引用次数：181 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、HIV Research and Treatment